New FDA Guidance Allows Use of KardiaMobile 6L to Measure QTc in COVID-19 Patients – AiThority

World’s only FDA-cleared six-lead personal ECG will be used by healthcare professionals to monitor QT duration in patients receiving medications that can cause potentially life threatening QT prolongation

AliveCor, the leader in artificial intelligence (AI)-based, personal ECG technology, and provider of enterprise cardiology solutions, announced that its KardiaMobile 6L – the world’s only six-lead personal ECG – is now allowed for use in the measurement of a patient’s QTc and detection of potentially dangerous QT prolongation.  A prolonged QTc can lead to a potentially fatal side effect, called drug-induced sudden cardiac death (DI-SCD), associated with the use of several medicines now being used in the treatment of COVID-19.

The QTc is a heart rate corrected interval that reflects the integrity of the heart’s electrical recharging system. Abnormal prolongation of the QTc can stem from congenital long QT syndrome, many disease states, electrolyte abnormalities, and over 100 FDA-approved medications that have the potential for unwanted QT prolongation. Patients with a prolonged QTc are at greater risk for their hearts to go into a potentially dangerous arrhythmia called Torsades de Pointes which can lead to sudden cardiac arrest and even worse, SCD. With the global pandemic of COVID-19 upon us, several drugs being used off-label to treat COVID-19 include Hydroxychloroquine and Azithromycin, have the potential for unwanted QT prolongation and worse, DI-SCD.

Recommended AI News: Source…

|

.